LAVA Therapeutics (LVTX) Competitors $1.54 -0.01 (-0.32%) As of 10:22 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LVTX vs. KYTX, ACTU, GLSI, BIOA, BDTX, IOBT, TIL, THTX, ALEC, and ACOGShould you be buying LAVA Therapeutics stock or one of its competitors? The main competitors of LAVA Therapeutics include Kyverna Therapeutics (KYTX), Actuate Therapeutics (ACTU), Greenwich LifeSciences (GLSI), BioAge Labs (BIOA), Black Diamond Therapeutics (BDTX), IO Biotech (IOBT), Instil Bio (TIL), Theratechnologies (THTX), Alector (ALEC), and Alpha Cognition (ACOG). These companies are all part of the "pharmaceutical products" industry. LAVA Therapeutics vs. Its Competitors Kyverna Therapeutics Actuate Therapeutics Greenwich LifeSciences BioAge Labs Black Diamond Therapeutics IO Biotech Instil Bio Theratechnologies Alector Alpha Cognition Kyverna Therapeutics (NASDAQ:KYTX) and LAVA Therapeutics (NASDAQ:LVTX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, media sentiment, dividends and institutional ownership. Does the media refer more to KYTX or LVTX? In the previous week, Kyverna Therapeutics had 4 more articles in the media than LAVA Therapeutics. MarketBeat recorded 9 mentions for Kyverna Therapeutics and 5 mentions for LAVA Therapeutics. Kyverna Therapeutics' average media sentiment score of 0.78 beat LAVA Therapeutics' score of 0.00 indicating that Kyverna Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyverna Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LAVA Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate KYTX or LVTX? Kyverna Therapeutics presently has a consensus target price of $15.60, indicating a potential upside of 336.97%. LAVA Therapeutics has a consensus target price of $2.69, indicating a potential upside of 74.92%. Given Kyverna Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Kyverna Therapeutics is more favorable than LAVA Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kyverna Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17LAVA Therapeutics 0 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is KYTX or LVTX more profitable? Kyverna Therapeutics' return on equity of -64.98% beat LAVA Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Kyverna TherapeuticsN/A -64.98% -56.17% LAVA Therapeutics N/A -98.08%-36.06% Which has more risk and volatility, KYTX or LVTX? Kyverna Therapeutics has a beta of 3.05, suggesting that its share price is 205% more volatile than the S&P 500. Comparatively, LAVA Therapeutics has a beta of 0.5, suggesting that its share price is 50% less volatile than the S&P 500. Which has higher earnings & valuation, KYTX or LVTX? LAVA Therapeutics has higher revenue and earnings than Kyverna Therapeutics. LAVA Therapeutics is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKyverna Therapeutics$7.03M21.96-$127.48M-$3.68-0.97LAVA Therapeutics$11.98M3.37-$25.11M-$1.04-1.48 Do institutionals & insiders believe in KYTX or LVTX? 18.1% of Kyverna Therapeutics shares are owned by institutional investors. 22.0% of Kyverna Therapeutics shares are owned by company insiders. Comparatively, 9.5% of LAVA Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. SummaryKyverna Therapeutics beats LAVA Therapeutics on 12 of the 16 factors compared between the two stocks. Get LAVA Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LVTX vs. The Competition Export to ExcelMetricLAVA TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$40.39M$3.12B$5.67B$9.80BDividend YieldN/A2.23%4.61%4.07%P/E Ratio-1.4620.7930.4125.56Price / Sales3.37359.38471.98115.12Price / CashN/A43.0338.2159.48Price / Book1.458.588.886.13Net Income-$25.11M-$54.65M$3.25B$265.06M7 Day Performance0.33%6.28%4.72%2.94%1 Month Performance9.64%9.20%6.73%3.32%1 Year Performance-15.66%13.63%30.24%25.08% LAVA Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LVTXLAVA Therapeutics2.0086 of 5 stars$1.54-0.3%$2.69+74.9%-13.0%$40.39M$11.98M-1.4660Earnings ReportUpcoming EarningsShort Interest ↓KYTXKyverna Therapeutics2.9348 of 5 stars$3.37-2.0%$15.60+362.9%-47.6%$148.67M$7.03M-1.0096News CoverageEarnings ReportAnalyst RevisionACTUActuate Therapeutics2.9757 of 5 stars$7.07-2.6%$20.50+190.0%-10.2%$148.62MN/A0.0010Positive NewsEarnings ReportGap UpGLSIGreenwich LifeSciences1.4631 of 5 stars$11.94+7.7%$39.00+226.6%-7.0%$148.26MN/A-9.483Earnings ReportBIOABioAge LabsN/A$4.42+7.3%N/AN/A$147.70MN/A0.00N/ABDTXBlack Diamond Therapeutics3.3406 of 5 stars$2.83+9.3%$12.80+352.3%-44.2%$147.27MN/A47.1790News CoverageAnalyst RevisionIOBTIO Biotech3.0549 of 5 stars$2.15-3.2%$9.33+334.1%-8.6%$146.26MN/A-1.4430News CoverageEarnings ReportAnalyst ForecastShort Interest ↑TILInstil Bio3.1253 of 5 stars$24.74+11.3%$119.00+381.0%+170.1%$145.80MN/A-2.07410Earnings ReportAnalyst ForecastTHTXTheratechnologiesN/A$3.16flatN/A+135.9%$145.30M$85.87M-16.63140Positive NewsShort Interest ↓ALECAlector3.9876 of 5 stars$1.55+6.9%$4.17+168.8%-49.4%$144.99M$100.56M-1.23270ACOGAlpha Cognition1.7654 of 5 stars$8.74-3.4%$20.00+128.8%N/A$144.98MN/A-7.28N/ANews Coverage Related Companies and Tools Related Companies Kyverna Therapeutics Alternatives Actuate Therapeutics Alternatives Greenwich LifeSciences Alternatives BioAge Labs Alternatives Black Diamond Therapeutics Alternatives IO Biotech Alternatives Instil Bio Alternatives Theratechnologies Alternatives Alector Alternatives Alpha Cognition Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LVTX) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LAVA Therapeutics N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share LAVA Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access